Markets:

Overview

News

Currencies

International

Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

71.28 -1.95 (-2.66%)

Streaming Delayed Price Updated: 11:13 AM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 07, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Insights into Halozyme Therapeutics's Upcoming Earnings ↗

May 05, 2025

Via Benzinga

While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable. ↗

April 26, 2025

HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Via Chartmill

Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings) ↗

April 25, 2025

Via Benzinga

Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief ↗

April 24, 2025

Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE...

Via Stocktwits

Topics Intellectual Property Lawsuit

Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts ↗

February 20, 2025

Via Benzinga

Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews ↗

February 04, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years ↗

April 22, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout. ↗

April 18, 2025

Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting ↗

April 11, 2025

FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.

Via Benzinga

Peering Into Halozyme Therapeutics's Recent Short Interest ↗

April 11, 2025

Via Benzinga

Investors should take notice of HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—it offers a great deal for the fundamentals it presents. ↗

April 10, 2025

HALOZYME THERAPEUTICS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:HALO showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

Analyst Expectations For Halozyme Therapeutics's Future ↗

January 13, 2025

Via Benzinga

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive. ↗

April 04, 2025

Uncover the potential of HALOZYME THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:HALO is excelling in growth aspects, maintaining a healthy financial position, and still offers an...

Via Chartmill

Is HALOZYME THERAPEUTICS INC (NASDAQ:HALO) a Minervini-style stock? ↗

March 31, 2025

Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) qualifies as a high growth stock. A fundamental and technical analysis of (NASDAQ:HALO).

Via Chartmill

Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase. ↗

March 27, 2025

Based on a technical and fundamental analysis of NASDAQ:HALO we can say: HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.

Via Chartmill

Looking for growth without the hefty price tag? Consider HALOZYME THERAPEUTICS INC (NASDAQ:HALO). ↗

March 14, 2025

HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

March 11, 2025

HALOZYME THERAPEUTICS INC has a stellar value proposition. NASDAQ:HALO not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Technical Analysis observations. ↗

March 06, 2025

Exploring HALOZYME THERAPEUTICS INC's Technical Signals and Breakout Potential: A technical analysis of HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows it may be setting up for a breakout.

Via Chartmill

NASDAQ:HALO: a strong growth stock preparing for the next leg up?. ↗

February 26, 2025

Based on a technical and fundamental analysis of NASDAQ:HALO we conclude: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

NASDAQ:HALO is not too expensive for the growth it is showing. ↗

February 17, 2025

HALOZYME THERAPEUTICS INC could be undervalued. NASDAQ:HALO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.

Via Chartmill

NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals. ↗

February 17, 2025

Discover HALOZYME THERAPEUTICS INC, an undervalued stock. NASDAQ:HALO showcases solid financial health and profitability while maintaining an appealing valuation.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why. ↗

February 03, 2025

A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article.

Via Chartmill

NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

February 03, 2025

Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.

Via Chartmill

Earnings Scheduled For February 18, 2025 ↗

February 18, 2025

Via Benzinga

In the world of growth stocks, NASDAQ:HALO shines as a value proposition. ↗

January 27, 2025

HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.

Via Chartmill

In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals. ↗

January 24, 2025

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

BeiGene Stock Meets 80-Plus RS Rating Benchmark ↗

January 15, 2025

One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.

Via Investor's Business Daily

BridgeBio Pharma Stock Earns 87 RS Rating ↗

January 14, 2025

BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.